Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache
Standard
Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. / Jürgens, Tim P; Barloese, Mads; May, Arne; Láinez, Jose Miguel; Schoenen, Jean; Gaul, Charly; Goodman, Amy M; Caparso, Anthony; Jensen, Rigmor Højland.
In: CEPHALALGIA, Vol. 37, No. 5, 04.2017, p. 423-434.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache
AU - Jürgens, Tim P
AU - Barloese, Mads
AU - May, Arne
AU - Láinez, Jose Miguel
AU - Schoenen, Jean
AU - Gaul, Charly
AU - Goodman, Amy M
AU - Caparso, Anthony
AU - Jensen, Rigmor Højland
N1 - © International Headache Society 2016.
PY - 2017/4
Y1 - 2017/4
N2 - OBJECTIVES: The sphenopalatine ganglion (SPG) plays a pivotal role in cluster headache (CH) pathophysiology as the major efferent parasympathetic relay. We evaluated the long-term effectiveness of SPG stimulation in medically refractory, chronic CH patients.METHODS: Thirty-three patients were enrolled in an open-label follow-up study of the original Pathway CH-1 study, and participated through 24 months post-insertion of a microstimulator. Response to therapy was defined as acute effectiveness in ≥ 50% of attacks or a ≥ 50% reduction in attack frequency versus baseline.RESULTS: In total, 5956 attacks (180.5 ± 344.8, range 2-1581 per patient) were evaluated. At 24 months, 45% (n = 15) of patients were acute responders. Among acute responders, a total of 4340 attacks had been treated, and in 78% of these, effective therapy was achieved using only SPG stimulation (relief from moderate or greater pain or freedom from mild pain or greater). A frequency response was observed in 33% (n = 11) of patients with a mean reduction of attack frequency of 83% versus baseline. In total, 61% (20/33) of all patients were either acute or frequency responders or both. The majority maintained their therapeutic response through the 24-month evaluation.CONCLUSIONS: In the population of disabled, medically refractory chronic CH patients treated in this study, SPG stimulation is an effective acute therapy in 45% of patients, offering sustained effectiveness over 24 months of observation. In addition, a maintained, clinically relevant reduction of attack frequency was observed in a third of patients. These long-term data provide support for the use of SPG stimulation for disabled patients and should be considered after medical treatments fail, are not tolerated or are inconvenient for the patients.
AB - OBJECTIVES: The sphenopalatine ganglion (SPG) plays a pivotal role in cluster headache (CH) pathophysiology as the major efferent parasympathetic relay. We evaluated the long-term effectiveness of SPG stimulation in medically refractory, chronic CH patients.METHODS: Thirty-three patients were enrolled in an open-label follow-up study of the original Pathway CH-1 study, and participated through 24 months post-insertion of a microstimulator. Response to therapy was defined as acute effectiveness in ≥ 50% of attacks or a ≥ 50% reduction in attack frequency versus baseline.RESULTS: In total, 5956 attacks (180.5 ± 344.8, range 2-1581 per patient) were evaluated. At 24 months, 45% (n = 15) of patients were acute responders. Among acute responders, a total of 4340 attacks had been treated, and in 78% of these, effective therapy was achieved using only SPG stimulation (relief from moderate or greater pain or freedom from mild pain or greater). A frequency response was observed in 33% (n = 11) of patients with a mean reduction of attack frequency of 83% versus baseline. In total, 61% (20/33) of all patients were either acute or frequency responders or both. The majority maintained their therapeutic response through the 24-month evaluation.CONCLUSIONS: In the population of disabled, medically refractory chronic CH patients treated in this study, SPG stimulation is an effective acute therapy in 45% of patients, offering sustained effectiveness over 24 months of observation. In addition, a maintained, clinically relevant reduction of attack frequency was observed in a third of patients. These long-term data provide support for the use of SPG stimulation for disabled patients and should be considered after medical treatments fail, are not tolerated or are inconvenient for the patients.
KW - Journal Article
U2 - 10.1177/0333102416649092
DO - 10.1177/0333102416649092
M3 - SCORING: Journal article
C2 - 27165493
VL - 37
SP - 423
EP - 434
JO - CEPHALALGIA
JF - CEPHALALGIA
SN - 0333-1024
IS - 5
ER -
